🔎 Trials Near Me

Home › Kidney Cancer (Renal Cell Carcinoma) › California

Kidney Cancer (Renal Cell Carcinoma) clinical trials in California

51 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in California.

Cities in California

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • Research Site, San Diego
  • Research Site, Santa Monica
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05536141

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

  • NEO-811 Los Angeles Site, Duarte
  • NEO-811 San Diego Site, San Diego
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07300241

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  • UCSF Medical Center at Mission Bay ( Site 5008), San Francisco
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT07049926

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  • University of California San Diego Moores Cancer Center, La Jolla
  • Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06234605

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
  • PCR Oncology, Arroyo Grande
  • AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
  • and 20 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #59, Santa Barbara
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

  • University of California Irvine, Orange
  • Stanford, Palo Alto
  • University of California San Francisco, San Francisco
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05287945

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Keck Medicine of USC Koreatown, Los Angeles
  • Los Angeles General Medical Center, Los Angeles
  • USC / Norris Comprehensive Cancer Center, Los Angeles
  • and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382

DESTINY-PANTUMOUR04

  • Research Site, San Diego
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • University of California San Diego, La Jolla
  • Stanford University, Palo Alto
  • UCLA Medical Center, Santa Monica
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Precision NextGen Oncology, Beverly Hills
  • OPN Healthcare, Inc, Glendale
  • University of Southern California, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

  • University of California San Diego, La Jolla
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06863311

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  • PCR Oncology, Arroyo Grande
  • Tower Cancer Research Foundation, Beverly Hills
  • Mills-Peninsula Medical Center, Burlingame
  • and 16 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
  • City of Hope Investigational Drug Services (IDS), Duarte
  • UC San Diego Medical Center - Encinitas, Encinitas
  • and 13 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07227415

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

  • USC Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04969315

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  • City of Hope Medical Center, Duarte
  • University of California San Diego Medical Center, Moores Cancer Center, La Jolla
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • University of California, San Diego, La Jolla
  • Hoag Memorial Hospital Presbyterian, Newport Beach
  • Redwood City, Redwood City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • Sutter Auburn Faith Hospital, Auburn
  • Tower Cancer Research Foundation, Beverly Hills
  • City of Hope Comprehensive Cancer Center, Duarte
  • and 23 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06661720

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT05830058

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • University of Southern California, Los Angeles
  • Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
  • Cedars-Sanai Medical Center, Los Angeles
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

  • UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06432036

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

  • City of Hope National Medical Center, Duarte
  • Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05361720

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Community Cancer Institute, Clovis
  • USC/Norris Comprehensive Cancer Center, Los Angeles
  • Hoag Memorial Hospital Presbyterian, Newport Beach
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

  • The Angeles Clinic and Research Institute, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

  • City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07226544

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  • Providence Medical Foundation ( Site 0141), Fullerton
  • USC Norris Comprehensive Cancer Center ( Site 0126), Los Angeles
  • Cedars-Sinai Medical Center ( Site 0112), Los Angeles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT07227402

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Duarte
  • Xencor Investigative Site, Sacramento
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • City of Hope, Duarte
  • Los Angeles Cancer Network, Glendale
  • California Research Institute, Los Angeles
  • and 3 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

  • University of California, San Francisco, San Francisco
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT07043608

Imaging of Solid Tumors Using 18F-TRX

  • University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06942104

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

  • City of Hope Medical Center, Duarte
  • City of Hope Medical Center, Irvine
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT07128680

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

  • University of California, Davis, Sacramento
Recruiting
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06101290

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

  • Start Lacn, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT07517198

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 9, 2026 · NCT07037004

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • University of Southern California, Los Angeles
  • Cedars-Sinai Medical Center, Los Angeles
  • UCLA Department of Medicine, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT06026410

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

  • City of Hope, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06053658

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.